Stephanie D. Geuns-Meyer

发表

Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index.

A. Cheng, J. Eksterowicz, Stephanie D. Geuns-Meyer, 2010, Journal of medicinal chemistry.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.

Stephanie D. Geuns-Meyer, N. Gavva, Y. Teffera, 2016, Journal of medicinal chemistry.

1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.

Kristin L. Andrews, R. Fremeau, M. Chu-Moyer, 2018, Bioorganic & medicinal chemistry letters.

Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones.

Stephanie D. Geuns-Meyer, H. Gunaydin, H. Nguyen, 2012, The Journal of organic chemistry.

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

T. Bush, Grace Chung, R. Radinsky, 2015, Journal of Medicinal Chemistry.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

T. Bush, Marc Payton, Grace Chung, 2010, Cancer research.

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

P. Gallant, M. Morrison, P. Rose, 2007, Bioorganic & medicinal chemistry letters.

Therapeutics , Targets , and Chemical Biology Preclinical Evaluation of AMG 900 , a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

T. Bush, Grace Chung, R. Radinsky, 2010 .

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

I. Archibeque, Stephanie D. Geuns-Meyer, R. Emkey, 2013, Experimental hematology.

Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats

C. Stucky, B. Moyer, Stephanie D. Geuns-Meyer, 2016, Molecular pain.

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Richard Kendall, P. Gallant, M. Morrison, 2007, Journal of medicinal chemistry.

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

Xin Huang, Christopher Mohr, Paul Hughes, 2009, Bioorganic & medicinal chemistry letters.

Development of novel azabenzofuran TRPA1 antagonists as in vivo tools.

Stephanie D. Geuns-Meyer, N. Gavva, A. Boezio, 2014, Bioorganic & medicinal chemistry letters.

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.

Xin Huang, Renee Emkey, A. Cheng, 2011, Journal of medicinal chemistry.

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

David Powers, Paul Hughes, Richard Kendall, 2007, Journal of medicinal chemistry.